03:08 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

Ghrelin’s LEAP forward

NGM and MedImmune researchers have discovered a liver peptide, LEAP2, that is a natural antagonist of the metabolic target ghrelin. The peptide could serve as a new handle for either boosting or dampening ghrelin signaling...
19:43 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity; cachexia Mouse and rat studies suggest GDF15 could help treat obesity, and inhibiting its receptor GFRAL could help treat cachexia. In a mouse model of high-fat diet-induced obesity and a genetic rat model of...
23:12 , Oct 2, 2017 |  BC Extra  |  Preclinical News

NGM targeting GFRAL for both obesity and cachexia

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) plans to develop separate candidates modulating GDNF family receptor alpha like (GFRAL) to treat both obesity and cachexia. In a newly published paper, an NGM team showed GFRAL...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
13:36 , Sep 14, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

New Therapeutic Targets and Biomarkers: August 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during August 2017. Therapeutic targets are defined as any protein, gene or other molecule...
17:33 , Aug 28, 2017 |  BC Extra  |  Preclinical News

Teams identify GFRAL as target for obesity

In three separate papers published in Nature Medicine on Monday, researchers at Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO), Eli Lilly and Co. (NYSE:LLY) and the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ)...